On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 737-747

  Man, Shan ^a   Munoz, Raquel ^a   Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Advanced visceral metastatic disease; Anti cancer drug testing; Antiangiogenic therapy; Metronomic chemotherapy; Refractory disease

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY DC101; OXALIPLATIN; PRODRUG; TAXANE DERIVATIVE; UFT; VINBLASTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; EXPERIMENTAL STUDY; HUMAN; IMMUNE DEFICIENCY; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VISCERAL METASTASIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; TEGAFUR; TRANSPLANTATION, HETEROLOGOUS; URACIL;

EID: 36148954658     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9087-6     Document Type: Review

References (37)

1. Sharpless, N. E., & DePinho, R. A. (2006). The mighty mouse: Genetically engineered mouse models in cancer drug development. Nature Reviews Drug Discovery, 5, 741-754.
2. Kelland, L. R. (2004). "Of mice and men": Values and liabilities of the athymic nude mouse model in anticancer drug development. European Journal of Cancer, 40, 827-836.
3. Kamb, A. (2005). What's wrong with our cancer models? Nature Reviews Drug Discovery, 4, 161-165.
4. Kung, A. L. (2007). Practices and pitfalls of mouse cancer models in drug discovery. Advances in Cancer Research, 96, 191-212.
5. Olive, K. P., & Tuveson, D. A. (2006). The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clinical Cancer Research, 12, 5277-5287.
6. Becher, O. J., & Holland, E. C. (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Research, 66, 3355-3358.
7. Kerbel, R. S. (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved. Cancer Biology & Therapy, 2, 108-113.
8. Sausville, E. A., & Burger, A. M. (2006). Contributions of human tumor xenografts to anticancer drug development. Cancer Research, 66, 3351-3354, discussion.
9. Hoffman, R. M. (2005). Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods in Molecular Medicine, 111, 297-322.
10. Inaba, M., Tashiro, T., Kobayashi, T., Sakurai, Y., Maruo, K., Ohnishi, Y., et al. (1988). Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Japanese Journal of Cancer Research, 79, 517-522.
11. Inaba, M., Kobayashi, T., Tashiro, T., Sakurai, Y., Maruo, K., Ohnishi, Y., et al. (1989). Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer, 64, 1577-1582.
12. Bibby, M. C. (2004). Orthotopic models of cancer for preclinical drug evaluation: advantages and disadavantages. European Journal of Cancer, 40, 852-857.
13. Chen, H. X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., et al. (2006). Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. Journal of Clinical Oncology, 24, 3354-3360.
14. Tripathy, D. (2007). Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: Underlying rationale and results of clinical trials. Oncologist, 12, 375-389.
15. Fidler, I. J. (1973). Selection of successive cell lines for metastasis. Nature New Biology, 242, 148-149.
16. Killion, J. J., Radinsky, R., & Fidler, I. J. (1998). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer and Metastasis Reviews, 17, 279-284.
17. Munoz, R., Man, S., Shaked, Y., Lee, C. R., Wong, J., Francia, G., et al. (2006). Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Research, 66, 3386-3391.
18. Stephenson, R. A., Dinney, C. P., Gohji, K., Ordonez, N. G., Killion, J. J., & Fidler, I. J. (1992). Metastatic model for human prostate cancer using orthotopic implantation in nude mice. Journal of the National Cancer Institute, 84, 951-957.
19. Dinney, C. P., Babkowski, R. C., Antelo, M., Perrotte, P., Liebert, M., Zhang H. Z., et al. (1998). Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. Journal of Urology, 160, 1285-1290.
20. Fidler, I. J. (1991). Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer and Metastasis Reviews, 10, 229-243.
21. Chen, C., Parangi, S., Tolentino, M. J., & Folkman, J. (1995). A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Research, 55, 4230-4233.
22. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
23. Browder, T., Butterfield, C. E., Kraling, B. M., Marshall, B., O'Reilly, M. S., & Folkman, J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research, 60, 1878-1886.
24. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., et al. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation, 105, R15-R24.
25. Hanahan, D., Bergers, G., & Bergsland, E. (2000). Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. Journal of Clinical Investigation, 105, 1045-1047.
26. Kerbel, R. S., & Kamen, B. A. (2004). Antiangiogenic basis of low-dose metronomic chemotherapy. Nature Reviews. Cancer, 4, 423-436.
27. Shaked, Y., Emmengger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y., et al. (2005). The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood, 106, 3058-3061.
28. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., et al. (1999). Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Research, 59, 5209-5218.
29. Fidler, I. J., & Ellis, L. M. (2000). Chemotherapeutic drugs-more really is not better. Nature Medicine, 6, 500-502.
30. Man, S., Bocci, G., Francia, G., Green S. K., Jothy, S., Hanahan, D., et al. (2002). Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Research, 62, 2731-2735.
31. Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., et al; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy (2004). A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. New England Journal of Medicine, 350, 1713-1721.
32. Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz T., et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell, 7, 101-111.
33. Nio, Y., Iguchi, C., Kodama, H., Itakura, M., Hashimoto, K., Koike M., et al. (2007). Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. Oncology Reports, 17, 153-159.
34. Cornil, I., Man, S., Fernandez, B., & Kerbel, R. S. (1989). Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. Journal of the National Cancer Institute, 81, 938-944.
35. Palmieri, D., Chambers, A. F., Felding-Habermann, B., Huang, S., & Steeg, P. S. (2007). The biology of metastasis to a sanctuary site. Clinical Cancer Research, 13, 1656-1662.
36. Cranmer, L. D., Trevor, K. T., Bandlamuri, S., & Hersh, E. M. (2005). Rodent models of brain metastasis in melanoma. Melanoma Research, 15, 325-356.
37. Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312, 1171-1175.